K
Kimberly N. Johnson
Researcher at Vanderbilt University Medical Center
Publications - 12
Citations - 1661
Kimberly N. Johnson is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Breast cancer & Regulation of gene expression. The author has an hindex of 12, co-authored 12 publications receiving 1270 citations. Previous affiliations of Kimberly N. Johnson include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann,Bojana Jovanovic,Xi Chen,Monica V. Estrada,Kimberly N. Johnson,Yu Shyr,Harold L. Moses,Melinda E. Sanders,Jennifer A. Pietenpol +8 more
TL;DR: Pre-clinical data is provided that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.
Journal ArticleDOI
Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression.
Jing Luan,Rebecca L. Shattuck-Brandt,Hamid Haghnegahdar,James D. Owen,Robert M. Strieter,Marie D. Burdick,Chaitanya S. Nirodi,Dan Beauchamp,Kimberly N. Johnson,Ann Richmond +9 more
TL;DR: It is proposed that this endogenous nuclear NF‐κB, working in concert with the 115‐κDa IUR‐binding factor, promotes constitutive expression of MGSA/GRO genes in immortalized melanocytes.
Journal ArticleDOI
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Joshua A. Bauer,A. Bapsi Chakravarthy,Jennifer M. Rosenbluth,Deming Mi,Erin H. Seeley,Nara De Matos Granja-Ingram,Maria Graciela Olivares,Mark C. Kelley,Ingrid A. Mayer,Ingrid M. Meszoely,Julie Means-Powell,Kimberly N. Johnson,Chiaojung Jillian Tsai,Gregory D. Ayers,Melinda E. Sanders,Robert J. Schneider,Silvia C. Formenti,Richard M. Caprioli,Jennifer A. Pietenpol +18 more
TL;DR: The results suggest the potential use of immune signaling molecules such as DEFA as well as MAP2, a microtubule-associated protein, as tumor markers that associate with response to neoadjuvant taxane–based therapy.
Journal ArticleDOI
TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
Brian D. Lehmann,Brian D. Lehmann,Vandana G Abramson,Vandana G Abramson,Melinda E. Sanders,Melinda E. Sanders,Erica L. Mayer,Tufia C. Haddad,Rita Nanda,Catherine Van Poznak,Anna Maria Storniolo,Julie R. Nangia,Paula I. Gonzalez-Ericsson,Paula I. Gonzalez-Ericsson,Violeta Sanchez,Kimberly N. Johnson,Richard G. Abramson,Sheau-Chiann Chen,Yu Shyr,Carlos L. Arteaga,Antonio C. Wolff,Jennifer A. Pietenpol,Jennifer A. Pietenpol +22 more
TL;DR: Correlative analyses suggest AR protein expression alone is insufficient for identifying patients with AR-dependent tumors and knowledge of tumor LAR subtype and AR splice variants may identify patients more or less likely to benefit from AR antagonists.
Journal ArticleDOI
IGFBP-3 Is a Direct Target of Transcriptional Regulation by ΔNp63α in Squamous Epithelium
Christopher E. Barbieri,Carmen A. Perez,Kimberly N. Johnson,Kim Ely,Dean Billheimer,Jennifer A. Pietenpol +5 more
TL;DR: Evidence is presented that DeltaNp63alpha functions to negatively regulate the proapoptotic protein IGFBP-3 and that this repression represents a mechanism by which tumors that overexpress p63 may be protected from apoptosis.